Latest Conference Articles

November 22nd 2020, 5:30pm

ESMO Asia Congress

Sotorasib was well tolerated and led to disease control in the majority of patients with heavily pretreated KRAS G12C–mutant gastrointestinal malignancies.

November 21st 2020, 6:00pm

ESMO Asia Congress

November 21, 2020 - The addition of sugemalimab to chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit in the frontline treatment of patients with metastatic non–small cell lung cancer versus placebo plus chemotherapy.

November 21st 2020, 5:13pm

ESMO Asia Congress

Timothy Price, MBBS, DHthSc, FRACP, discusses the safety and efficacy of AMG 510 in patients with advanced gastrointestinal cancers.

November 21st 2020, 5:01pm

ESMO Asia Congress

Maurice Perol, MD, discusses combination regimens comprised of chemotherapy and EGFR TKIs in the treatment of patients with EGFR-mutated advanced non–small cell lung cancer, as investigated in the OPAL trial presented during the ESMO Asia Virtual Congress 2020.

November 21st 2020, 4:19pm

ESMO Asia Congress

November 21, 2020 - Frontline sintilimab injection in combination with bevacizumab biosimilar injection resulted in a significant improvement in overall survival and progression-free survival per Independent Radiographic Review Committee versus sorafenib in patients with advanced unresectable hepatocellular carcinoma.

November 21st 2020, 3:23pm

ESMO Asia Congress

November 21, 2020 — Maintenance niraparib, when administered at an individualized starting dose, led to a 70% reduction in the risk of disease progression or death compared with placebo in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy.

November 20th 2020, 11:16pm

ESMO Asia Congress

The combination of atezolizumab and nab-paclitaxel led to a clinically meaningful overall survival benefit in treatment-naïve patients with locally advanced or metastatic triple-negative breast cancer who had PD-L1 expressing tumor-infiltrating immune cells.

November 20th 2020, 8:55pm

ESMO Asia Congress

November 20, 2020 - Patients from Asian countries with hormone receptor–positive, HER2-negative breast cancer may have a higher risk of disease recurrence than those from non-Asian countries, suggesting that this population may benefit from additional adjuvant treatment with abemaciclib.

November 20th 2020, 6:32pm

ESMO Asia Congress

November 20, 2020 - Osimertinib in combination with platinum plus pemetrexed was well tolerated in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer.

November 20th 2020, 6:20pm

ESMO Asia Congress

The noninvasive blood-based targeted methylation assay ELSA-seq identified early cancers with high specificity and provided accurate predictions of the tissue of origin.